Company Profile
Brainstorm Cell Therapeutics Inc. Stock Price, News & Analysis
Company overview
Business overview
Brainstorm Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Brainstorm Cell Therapeutics sits inside the cell therapy universe where trial execution and regulatory timing can change the investment case quickly.
Business Model Characteristics
Brainstorm Cell Therapeutics follows a platform-led model where readouts, manufacturing progress, and commercialization milestones matter as much as the initial science. The market tends to reprice the stock quickly whenever adoption, safety, or label-expansion signals improve.
Position Within the Biotechnology Landscape
Compared with larger diversified biotech peers, Brainstorm Cell Therapeutics sits at the high-catalyst end of the landscape, where cell therapy names can move sharply on data, approvals, and launch milestones.
Why the stock is moving
BCLI is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
BrainStorm's ALS program is still the main thing to follow. The planned Phase 3 study is built around a fairly specific two-part design, and the next meaningful step is simply whether the company can keep that plan moving with funding and execution intact.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Source: Brainstorm Cell Therapeutics Inc.
- 02
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Source: Brainstorm Cell Therapeutics Inc.
- 03
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
Source: Brainstorm Cell Therapeutics Inc.
- 04
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
Source: Brainstorm Cell Therapeutics Inc.
- 05
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
Source: Brainstorm Cell Therapeutics Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.